Home / Healthcare/ GSK’s new triple lung drug beats other modern inhalers in study

GSK’s new triple lung drug beats other modern inhalers in study


Comments / {{hitsCtrl.values.hits}} Views / Wednesday, 27 September 2017 00:00


London (Reuters): GlaxoSmithKline produced clinical data on Wednesday showing its newly approved three-in-one inhaler reduced life-threatening attacks in chronic obstructive pulmonary disease (COPD) patients more than other modern treatments.

Britain’s biggest drugmaker believes the results confirm the potential of the once-daily single inhaler, Trelegy Ellipta, a product it hopes will offset the impact of generic competition to the older lung drug Advair.

Trelegy won approval based on clinical tests showing it improved lung function and exacerbations more than AstraZeneca’s long-established two-drug inhaler Symbicort, which works in a similar way to Advair.

The latest clinical trial, however, compares Trelegy to two more modern two-drug combinations and was seen as a more critical test for doctors wanting to know if the new product really delivers an added benefit.

The IMPACT study, which involved 10,355 patients, showed Trelegy delivered statistically significant reductions in the rate of annual exacerbations, or attacks, compared with both Breo and Anoro, two other relatively new GSK medicines.

GSK and its partner Innoviva plan to submit the latest data from the so-called IMPACT trial to regulatory authorities from the second quarter of 2018, with the aim of expanding the indicated patient population for Trelegy.


Share This Article


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Ranil’s tactical success, Mahinda’s strategic victory

Wednesday, 21 February 2018

Who will defeat the UNP? The people, with or without the Sri Lanka Freedom Party. That was proved at the local government


Betraying the very foundation of the Unity Government- Consensus

Wednesday, 21 February 2018

Soon after the results of the Local Government bodies were released, it was reported that the President wanted the resignation of the Prime Minister


Sri Lankan consumer under pressure

Wednesday, 21 February 2018

Whilst Sri Lanka is grappling to understand how to structure the Government to run the country, the reality is thWhilst Sri Lanka


More of the same

Tuesday, 20 February 2018

Those of you who’ve read what I have written over the years could, justifiably, experience a sense of déjà vu as you read what follows. That said, I will make no apology for the burden of this piece because it will, again, state the eternal verit


Columnists More